Jacobio Pharmaceuticals Co., Ltd.

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A First in Human, Dose Escalation Study of JAB-3068 （SHP2 Inhibitor） in Adult Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Non-small Cell Lung Cancer
Head and Neck Cancer
Esophageal Cancer
Other Metastatic Solid Tumors

Interventions: Drug: JAB-3068

First Posted Date: 2018-05-08

Last Posted Date: 2024-12-16

Lead Sponsor: Jacobio Pharmaceuticals Co., Ltd.

Target Recruit Count: 38

Registration Number: NCT03518554

Locations: 🇺🇸
HealthONE Clinic Services Oncology-Hematology, Denver, Colorado, United States
🇺🇸
Sarah Cannon Research Institute, Nashville, Tennessee, United States
🇺🇸
Florida Cancer Specialists, Sarasota, Florida, United States

and more 1 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy